secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001730463-24-000004
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus appoints Robert Azelby to Board, commercial focus as BLA for obe-cel submitted
--------------------------------------------------------------------------------

- Robert W. Azelby appointed Class II director effective Jan 9, 2024; brings 30+ years biopharma commercial experience.
- Initial option grant of 80,000 ADSs at $6.84/share; annual retainer £52,500 plus £3,500 for committee service.
- Azelby was CEO of Eliem Therapeutics and Alder BioPharmaceuticals; served at Juno and Amgen.
- Company recently submitted BLA for lead CAR T therapy obe-cel; Azelby to aid commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/0001730463-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/autl-20240109.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer